The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.m

ILD with a granulomatous component

Publications

Paris A, Goupil F, Kernaonet E, Foulet-Rogé A, Molinier O, Gagnadoux F, Lebas FX

[Drug-induced pneumonitis due to sirolimus: an interaction with atorvastatin?].

Revue des maladies respiratoires. 2012;29(1):64-9

Sola E, Lopez V, Burgos D, Cabello M, Gutierrez C, Martin A, Peña M, Gonzalez-Molina M

Pulmonary toxicity associated with sirolimus treatment in kidney transplantation.

Transplantation proceedings. 2006;38(8):2438-40

Howard L, Gopalan D, Griffiths M, Mahadeva R

Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate.

Chest. 2006;129(6):1718-21

Chhajed PN, Dickenmann M, Bubendorf L, Mayr M, Steiger J, Tamm M

Patterns of pulmonary complications associated with sirolimus.

Respiration; international review of thoracic diseases. 2006;73(3):367-74

Morelon E, Stern M, Israël-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, Peraldi MN, Kreis H

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.

Transplantation. 2001;72(5):787-90